Catalysts
EXAS Stock Catalysts
Earnings · Growth Drivers · Events · AIQ Catalyst
EXAS
CatalystsStock Catalyst Board
Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.
No upcoming reporting date is available yet.
Momentum — and sentiment — before the next covered event.
Updated Sep 5, 2026 · Sentiment 19.86%
Earnings History And Surprises
See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.
Earnings Expectations And Results
Compare what analysts expected with what the company reported across recent quarters.
| Report date | Fiscal period | EPS estimate | EPS actual | EPS surprise | Revenue estimate | Revenue actual |
|---|---|---|---|---|---|---|
| Feb 13, 2026 | — | -$0.11 | -$0.45 | -316.9% | $860.9M | $878.38M |
| Nov 3, 2025 | — | -$0.06 | $0.24 | +492.0% | $810.51M | $850.74M |
| Aug 6, 2025 | — | -$0.02 | $0.22 | +1200.0% | $810.06M | $811.09M |
| May 1, 2025 | — | -$0.37 | -$0.54 | -45.9% | $688.65M | $706.79M |
| Feb 19, 2025 | — | -$0.29 | -$0.06 | +79.3% | $697.89M | $713.42M |
| Nov 5, 2024 | — | -$0.20 | -$0.21 | -7.2% | $716.8M | $708.66M |
| Jul 31, 2024 | — | -$0.37 | -$0.09 | +75.7% | $690M | $699.26M |
| May 8, 2024 | — | -$0.47 | -$0.50 | -5.3% | $627.35M | $637.52M |
Analyst Forecast And Price Targets
Wall Street consensus, rating distribution, and the current 12-month target range.
Event Read
Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.
Current event setup
Upcoming earnings date not available yet.
Current analyst expectation for the upcoming report.
Current analyst expectation for the upcoming report.
News pressure around the setup.
Where event reaction would show up first.
Composite decision read before event confirmation.
Analyst context
News And Sentiment
Recent company coverage, scored where source sentiment is available.
Jeremy Grantham’s Latest Portfolio: Microsoft, Alphabet Dominate GMO Holdings
Jeremy Grantham reported an equity portfolio valued at approximately $39.10 billion in the latest quarter, reflecting GMO's long-standing focus on high-quality businesses with durable competitive advantages and strong long-term earnings power. The portfolio remains broadly diversified across technology, healthcare, financials, and industrials, while maintaining meaningful concentration in a select group of large-cap holdings. The latest
Related Links
EXAS Catalysts FAQ
What are the next catalysts for EXAS stock?
EXAS's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.
What upcoming events could move EXAS stock?
Upcoming events that could move EXAS include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.
How could EXAS's next earnings report affect the stock?
EXAS's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.
What could drive EXAS stock higher?
EXAS could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.
What events could hurt EXAS stock?
EXAS could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.